Genomic Health, Inc. has announced it will present several studies during the 2014 Society of Urologic Oncology (SUO) Annual Meeting, including the second clinical validation study of the Oncotype DX prostate cancer test.
Oncotype DX Prostate Cancer Assay is a genomic test performed on a patient’s needle biopsy and provides essential information regarding the biology of a patient’s prostate cancer. The results are reported as the Genomic Prostate Score or GPS, and provide a more precise, accurate, and individualized risk assessment, to help the patient and his physician decide between active surveillance and immediate treatment. The GPS works in conjunction with standard guidelines to determine prostate cancer risk, from very low to intermediate. Within each of these risk groups, the lower the GPS, the more favorable tumor biology, and the less likely it is for a patient to begin immediate treatment with surgery or radiation.
The results to be presented are the latest in the validation of this test, and were developed together with the Center for Prostate Disease Research. Importantly, the study has been accepted for publication in the peer-reviewed journal European Urology.
Additionally, the results of the decision impact study of Oncotype DX developed together with Columbia University, Delaware Valley Urology and Orange County Urology, have been accepted for publication in the journal Urology Practice.
Alongside these studies, Genomic Health will show the results from the first liquid biopsy study, which evaluated the capacity of different technologies such as next-generation sequencing to detect and analyze the presence of bladder cancer biomarkers in a patient’s urine.
These studies reflect the company’s significant progress in the creation of a proprietary liquid biopsy platform.
The SUO Annual Meeting will take place Wednesday, December 3 at the North Marriott Hotel & Conference Center in Rockville, Md, and Genomic Health has three scheduled poster presentations, titled “A Biopsy-Based 17-gene Genomic Prostate Score Predicts Adverse Surgical Pathology and Recurrence After Radical Prostatectomy in Men with Clinically Low and Intermediate-Risk Prostate Cancer“, “The Impact of the Oncotype DX Genomic Prostate Score (GPS) on Initial Treatment Recommendations for Men with Newly Diagnosed Clinically Low-Risk Prostate Cancer” and “Next-Generation Sequencing of DNA from Urine Detects Multiple Bladder Tumor-Derived Alterations and Additional Changes that Suggest Tumor Heterogeneity“.